We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Iterum Therapeutics

News List

Iterum Therapeutics Submits NDA for Oral Sulopenem americanpharmaceuticalreview
December 16, 2020
Iterum Therapeutics has submitted its New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for sulopenem etzadroxil/probenecid (oral sulopenem) for the treatment of uncomplicated urinary tract infections (uUTIs) in patients with a ...
Iterum hit by failure of anti-infective sulopenem pharmatimes
June 04, 2020
Shares in Dublin, Ireland and Chicago, US-based Iterum Therapeutics have taken a hit on news that the firm's sulopenem did not achieve statistical non-inferiority relative to ertapenem in a trial in complicated urinary tract infection (cUTI).
Iterum files for $92M IPO to bankroll phase 3 trials of ex-Pfizer antibiotic fiercebiotech
May 02, 2018
Iterum Therapeutics filed to raise $92 million in an IPO that will support the phase 3 clinical trials of oral and intravenous versions of the antibiotic sulopenem.
Iterum Therapeutics Presents Data on Prevalence of Resistant Infections and Activity of its Novel Antibiotic Sulopenem biospace
April 23, 2018
Iterum Therapeutics plc, will deliver a mini-oral presentation and two additional posters at the European Congress of Clinical Microbiology in Madrid, Spain from April 21 to 24, 2018.